Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
Individuals previously infected with the novel coronavirus respond very strongly to single dose of their Pfizer-BioNTech COVID-19 vaccine, no matter if they were infected and whether they had detectable antibodies against the disease prior to receiving the preventive, according to a study.
Researchers from Bar-Ilan University and Ziv Medical Center in Israel noted that the real-world evidence with regard to the COVID-19 vaccine remains scarce even though the clinical trial data are encouraging.
Specifically, the answer to the COVID-19 vaccine among those previously infected with the SARS-CoV-2 virus is still not completely known, they said.
Antibody levels of the entire cohort were measured prior to vaccination and thereafter to determine reaction to the BNT162b2 mRNA vaccine developed by US company Pfizer and its German partner BioNTech.
The response among those previously infected was so powerful that it opens the debate as to whether one dose of the vaccine may deteriorate, the researchers said.
“This finding can help countries make informed decisions regarding vaccine coverage — for instance, whether those previously infected should be vaccinated in priority and, if so, with how many doses,” said Professor Michael Edelstein, from Bar-Ilan University, who led the study.
“It also offers reassurance that not having detectable antibodies after being infected does not necessarily indicate that protection following infection is lost,” Edelstein said.
The study also provides evidence that immune response was similar across multi-ethnic groups as Ziv Medical Center, where the study was conducted, is staffed by a workforce comprised of Jews, Arabs and Druze, amongst others.
The researchers said that the members of all those groups responded very similarly to the first dose of the vaccine, a welcome finding considering that the virus itself is known to affect some groups more than others.
The strong response to one dose of the vaccine among those previously infected whatever the duration between infection and vaccination is good news, they said.
The team continues to follow healthcare workers after their next dose to better understand how long the vaccine will protect against COVID-19 in different groups of people.
